Trial of MK-2206 + Endocrine Treatment in Patients With Hormone Receptor Positive Breast Cancer
This is a phase II Trial of MK-2206 in combination with Endocrine Therapy in patients with Hormone Receptor Breast Cancer. After the maximum tolerated dose is determined in the phase 1b trial (under a separate NCT number), efficacy will be evaluated among 17 patients.
Metastatic Breast Cancer
DRUG: MK-2206|DRUG: Exemestane|DRUG: Goserelin
Efficacy endpoint: Antitumor activity of MK-2206 when combined with exemestane +/- goserelin in pre- and post-menopausal patients with hormone receptor positive metastatic breast cancer, measured by clinical benefit rate., Clinical benefit rate is defined as complete response + partial response + stable disease for at least 24 weeks following initiation of treatment., 24 weeks (6 cycles)
The safety and tolerability of MK-2206 given in combination with exemestane +/- goserelin in pre- and post-menopausal patients with hormone receptor positive metastatic breast cancer., every four weeks (1 cycle)|Characterize the effect of MK-2206 in combination with exemestane +/- goserelin based on PI3K, AKT, and PTEN mutations, tumor blocks to be obtained prior to beginning the trial
This is a phase II Trial of MK-2206 in combination with Endocrine Therapy in patients with Hormone Receptor Breast Cancer. After the maximum tolerated dose is determined in the phase 1b trial (under a separate NCT number), efficacy will be evaluated among 17 patients.